Clovis Oncology, Inc.
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 2009-01-01
- Employees
- 413
- Market Cap
- -
- Website
- http://clovisoncology.com
Clinical Trials
76
Trial Phases
3 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (66 trials with phase data)• Click on a phase to view related trials
A Study to Evaluate Lucitanib in Combination With Nivolumab in Patients With a Solid Tumor
- Conditions
- Advanced Solid TumorGynecologic Cancer
- Interventions
- First Posted Date
- 2019-08-01
- Last Posted Date
- 2022-12-20
- Lead Sponsor
- Clovis Oncology, Inc.
- Target Recruit Count
- 227
- Registration Number
- NCT04042116
- Locations
- 🇺🇸
UCLA Jonsson Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸UC San Diego Moores Cancer Center, San Diego, California, United States
🇺🇸Anschutz Cancer Pavilion, Aurora, Colorado, United States
A Phase 1b/2 Study of Safety and Efficacy of Rociletinib in Combination With MPDL3280A in Patients With Advanced or Metastatic EGFR-mutant NSCLC
- First Posted Date
- 2015-12-15
- Last Posted Date
- 2019-07-05
- Lead Sponsor
- Clovis Oncology, Inc.
- Target Recruit Count
- 3
- Registration Number
- NCT02630186
- Locations
- 🇺🇸
University of California at Los Angeles, Santa Monica, California, United States
Phase 1/2 Study of the Safety and Efficacy of Rociletinib in Combination With Trametinib in Patients With mEGFR-positive Advanced or Metastatic Non-small Cell Lung Cancer
- First Posted Date
- 2015-10-20
- Last Posted Date
- 2018-10-02
- Lead Sponsor
- Clovis Oncology, Inc.
- Target Recruit Count
- 7
- Registration Number
- NCT02580708
- Locations
- 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States
🇺🇸Levine Cancer Institute, Charlotte, North Carolina, United States
🇺🇸Tennessee Oncology, PLLC - The Sarah Cannon Research Institute, Nashville, Tennessee, United States
Rociletinib (CO-1686) USA Expanded Access Program
- Conditions
- Non-small Cell Lung Cancer
- First Posted Date
- 2015-09-11
- Last Posted Date
- 2018-09-25
- Lead Sponsor
- Clovis Oncology, Inc.
- Registration Number
- NCT02547675
- Locations
- 🇺🇸
Mayo Clinic Arizona, Scottsdale, Arizona, United States
🇺🇸Compassionate Care Research Group, Inc., Fountain Valley, California, United States
🇺🇸Pacific Cancer Care, Monterey, California, United States
TIGER-3: Open Label, Multicenter Study of Rociletinib (CO-1686) Mono Therapy Versus Single-agent Cytotoxic Chemotherapy in Patients With Mutant EGFR NSCLC Who Have Failed at Least One Previous EGFR-Directed TKI and Platinum-doublet Chemotherapy
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- First Posted Date
- 2014-12-23
- Last Posted Date
- 2019-08-14
- Lead Sponsor
- Clovis Oncology, Inc.
- Target Recruit Count
- 149
- Registration Number
- NCT02322281
- Locations
- 🇺🇸
Comprehensive Blood and Cancer Center, Bakersfield, California, United States
🇺🇸City of Hope Cancer Center, Duarte, California, United States
🇺🇸Saint Joseph Heritage Healthcare, Fullerton, California, United States
- Prev
- 1
- 2
- 3
- Next